BIOA

Company Overview — What Does BioAge Labs, Inc. Do?

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Our primary focus is metabolic disease, one of the greatest global healthcare challenges. Azelaprag, our lead product candidate, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials. In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. We plan to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 clinical trials. While the results of these preclinical studies and early clinical trials have demonstrated the potential use of azelaprag for the treatment of metabolic disease, they may not be predictive of the results of later-stage clinical trials. The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound® by Eli Lilly and Company (Lilly), with topline results anticipated in the third quarter of 2025. The second Phase 2 clinical trial will assess azelaprag in combination with semaglutide, marketed as Wegovy® by Novo Nordisk, with initiation expected in the first half of 2025 and topline results expected in the second half of 2026. We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity. We also intend to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion. We expect to report topline results from this proof-of-concept trial in the second half of 2025. We are also developing orally available small molecule brain-penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. We anticipate submitting an Investigational New Drug application (IND) for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026. Our approach: Targeting human aging biology to treat chronic metabolic diseases The burden of many serious and chronic diseases—including cardiovascular disease and diabetes—increases with age. However, there is substantial natural variation in the human population, resulting in a broad range of aging trajectories and outcomes, with some people experiencing much longer lifespans as well as delayed disease onset. We created our company to identify biological pathways associated with longer, healthier human lifespans and to develop pharmaceutical products that can modulate these pathways with the intent to prevent and reverse specific diseases, focusing on metabolic diseases. --- Our approach starts with human data. We examine the impact of the molecular changes that happen naturally as people age and study how these changes drive both functional decline (e.g., loss of muscle strength) and disease risk (e.g., obesity, insulin resistance, dyslipidemia, hypertension). To develop new insights into the biological drivers of aging, we have generated proprietary longitudinal human datasets based on exclusive access to a unique resource: serial biobanked human samples coupled with health records and functional measurements collected for up to 50 years, capturing individual aging trajectories measured over several decades. We analyze these samples using state-of-the-artmolecular profiling technologies, measuring thousands of biologically relevant molecules, and then apply computational tools to the resulting data to extract potential drivers of a long and healthy lifespan. --- We have selected chronic metabolic diseases as our primary focus within age related chronic diseases, given their high prevalence and resulting potential for impact on population health. Chronic metabolic diseases represent some of the largest addressable therapeutics markets. Through our approach, we expect to target outsized commercial opportunities, initially within the obesity and diabetes landscape. For instance, according to third-party estimates, the global market for GLP-1R agonists, including those used to treat diabetes, is expected to grow to $150 billion by 2031. We were incorporated under the laws of the State of Delaware on April 1, 2015, under the name BioAge Labs, Inc. Our principal executive offices are located at 1445A South 50th Street, Richmond, California. BioAge Labs, Inc. (BIOA) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Kristen Fortney, headquartered in RICHMOND, California. With a market capitalization of $787M, BIOA is one of the notable companies in the Healthcare sector.

BioAge Labs, Inc. (BIOA) Stock Rating — Reduce (April 2026)

As of April 2026, BioAge Labs, Inc. receives a Reduce rating with a composite score of 39.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.BIOA ranks #3,119 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, BioAge Labs, Inc. ranks #455 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

BIOA Stock Price and 52-Week Range

BioAge Labs, Inc. (BIOA) currently trades at $16.30. The stock lost $1.49 (8.4%) in the most recent trading session. The 52-week high for BIOA is $24.00, which means the stock is currently trading -32.1% from its annual peak. The 52-week low is $2.88, putting the stock 466.0% above its annual trough. Recent trading volume was 294K shares, suggesting relatively thin trading activity.

Is BIOA Overvalued or Undervalued? — Valuation Analysis

BioAge Labs, Inc. (BIOA) carries a value factor score of 23/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.87x, versus the sector average of 2.75x. The price-to-sales ratio is 132.08x, compared to 1.66x for the average Healthcare stock.

At current multiples, BioAge Labs, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

BioAge Labs, Inc. Profitability — ROE, Margins, and Quality Score

BioAge Labs, Inc. (BIOA) earns a quality factor score of 27/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -28.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -26.5% versus the sector average of -33.1%.

On a margin basis, BioAge Labs, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -1095.7% (sector: -66.1%). Net profit margin stands at -922.3%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

BIOA Debt, Balance Sheet, and Financial Health

BioAge Labs, Inc. has a debt-to-equity ratio of 8.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 14.24x, indicating strong short-term liquidity. Total debt on the balance sheet is $4M. Cash and equivalents stand at $216M.

BIOA has a beta of 0.77, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for BioAge Labs, Inc. is 41/100, reflecting average volatility within the normal range for its sector.

BioAge Labs, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, BioAge Labs, Inc. reported revenue of $6M and earnings per share (EPS) of $-2.24. Net income for the quarter was $-78M. Gross margin was 100.0%. Operating income came in at $-89M.

In FY 2025, BioAge Labs, Inc. reported revenue of $9M and earnings per share (EPS) of $-2.24. Net income for the quarter was $-81M. Operating income came in at $-93M.

In Q3 2025, BioAge Labs, Inc. reported revenue of $2M and earnings per share (EPS) of $-0.56. Net income for the quarter was $-20M. Operating income came in at $-23M.

In Q2 2025, BioAge Labs, Inc. reported revenue of $2M and earnings per share (EPS) of $-0.60. Net income for the quarter was $-22M. Operating income came in at $-25M.

Over the past 8 quarters, BioAge Labs, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $6M. Investors analyzing BIOA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

BIOA Dividend Yield and Income Analysis

BioAge Labs, Inc. (BIOA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

BIOA Momentum and Technical Analysis Profile

BioAge Labs, Inc. (BIOA) has a momentum factor score of 77/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 24/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

BIOA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, BioAge Labs, Inc. (BIOA) ranks #455 out of 838 stocks based on the Blank Capital composite score. This places BIOA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing BIOA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BIOA vs S&P 500 (SPY) comparison to assess how BioAge Labs, Inc. stacks up against the broader market across all factor dimensions.

BIOA Next Earnings Date

No upcoming earnings date has been announced for BioAge Labs, Inc. (BIOA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy BIOA? — Investment Thesis Summary

The quantitative profile for BioAge Labs, Inc. suggests caution. The quality score of 27/100 flags below-average profitability. The value score of 23/100 indicates premium valuation. Price momentum is positive at 77/100, suggesting the trend favors buyers.

In summary, BioAge Labs, Inc. (BIOA) earns a Reduce rating with a composite score of 39.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BIOA stock.

Related Resources for BIOA Investors

Explore more research and tools: BIOA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BIOA head-to-head with peers: BIOA vs AZN, BIOA vs SLGL, BIOA vs VMD.